Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.06 USD | -0.33% | -4.08% | +51.49% |
May. 10 | Leerink Partners Starts Aquestive Therapeutics With Outperform Rating, $8 Price Target | MT |
May. 08 | Transcript : Aquestive Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024 |
Financials (USD)
Sales 2024 * | 50.02M | Sales 2025 * | 58.76M | Capitalization | 279M |
---|---|---|---|---|---|
Net income 2024 * | -45M | Net income 2025 * | -37M | EV / Sales 2024 * | 5.52 x |
Net cash position 2024 * | 2.63M | Net Debt 2025 * | 15.47M | EV / Sales 2025 * | 5 x |
P/E ratio 2024 * |
-5.65
x | P/E ratio 2025 * |
-7.37
x | Employees | 135 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.06% |
Latest transcript on Aquestive Therapeutics, Inc.
1 day | -0.33% | ||
1 week | -4.08% | ||
Current month | -8.93% | ||
1 month | -24.82% | ||
3 months | -4.38% | ||
6 months | +57.73% | ||
Current year | +51.49% |
Managers | Title | Age | Since |
---|---|---|---|
Daniel Barber
CEO | Chief Executive Officer | 48 | 07-06-30 |
A. Toth
DFI | Director of Finance/CFO | 65 | 20-12-30 |
Stephen Wargacki
CTO | Chief Tech/Sci/R&D Officer | 46 | 14-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Timothy Morris
BRD | Director/Board Member | 61 | 22-08-09 |
Santo Costa
BRD | Director/Board Member | 78 | 15-11-30 |
Gregory Brown
CHM | Chairman | 70 | 07-02-28 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-24 | 3.06 | -0.33% | 752,404 |
24-05-23 | 3.07 | -2.54% | 1,236,079 |
24-05-22 | 3.15 | -0.94% | 548,865 |
24-05-21 | 3.18 | -0.31% | 680,686 |
Delayed Quote Nasdaq, May 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+51.49% | 279M | |
+38.51% | 727B | |
+31.81% | 594B | |
-6.23% | 354B | |
+18.78% | 328B | |
+1.35% | 277B | |
+14.64% | 243B | |
+7.53% | 205B | |
-6.09% | 203B | |
+6.19% | 164B |
- Stock Market
- Equities
- AQST Stock